www.fdanews.com/articles/113595-fda-cites-humira-promotions-for-minimizing-risks
FDA Cites Humira Promotions for Minimizing Risks
January 9, 2009
Abbott Laboratories broadened the psoriasis indication for its Humira drug, a tumor necrosis factor inhibitor, in a professional advertisement and minimized the risks of the product by including them in small type, according to an FDA untitled letter. The limitations of the drug’s indication were not appropriately disseminated in the advertisement that ran in an American Academy of Dermatology “Post Meeting News Ad,” according to the letter.
Washington Drug Letter
Washington Drug Letter